MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, reported new real-world evidence from a multi-site quality improvement program with Vibra Healthcare, demonstrating that home-based rehabilitation using MindMotion significantly increases therapy dose and improves functional outcomes. Presented at the American Congress of Rehabilitation Medicine (ACRM) annual meeting, the findings highlight a potential solution to the well-documented gap in care that occurs after patients leave the clinic, a gap that often limits recovery for individuals with neurological conditions such as stroke.
The program evaluated 177 rehabilitation episodes involving 172 adults across four Vibra Healthcare outpatient sites. Participants used MindMotion GO for an eight-week home-training program, with optional four-week extension and periodic therapist supervision. Results showed a median threefold increase in total motor-training dose compared to usual outpatient therapy alone, with 84% of active training completed independently. This matters because higher therapy dose is strongly associated with better functional outcomes after neurological injury, yet access to intensive therapy is often constrained by cost, geography, and clinician shortages. By enabling patients to continue high-dose training at home, MindMaze's approach could help address these barriers.
Functional improvements were statistically significant across multiple measures: independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points), and mobility (Timed Up and Go: −8.8 seconds). High patient satisfaction was also reported, with 83.8% of satisfaction ratings positive. These outcomes are particularly important because they suggest that remote, gamified neurorehabilitation can deliver meaningful gains even without constant therapist oversight. The full poster, titled High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence.
The implications extend beyond clinical metrics. With an aging population and rising incidence of stroke and other neurological disorders, healthcare systems face mounting pressure to provide effective, scalable rehabilitation. MindMaze's strategy of extending its high-dose, high-intensity therapy from inpatient to home settings aligns with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery, which emphasizes the importance of continued therapy after discharge. The upcoming launch of MindMotion Lite, a tablet-based solution expected by year-end 2026, aims to further simplify home deployment by reducing hardware requirements while preserving the full range of MindMotion GO activities. Recently announced, MindMotion Lite could broaden adoption by healthcare providers and make neurorehabilitation more accessible to patients at home.
For investors and industry observers, the results reinforce MindMaze's position in the growing digital neurotherapeutics market. The company's FDA-listed and CE-marked products, combined with its extensive clinical validation, aim to address the systemic shortage of specialized clinicians. By demonstrating that home-based therapy can achieve substantial dose increases and functional gains, MindMaze is making a case for reimbursable, scalable solutions that could transform post-acute care. As Zach Henderson, CEO of MindMaze Therapeutics, noted, these milestones bring the company closer to its mission of making neurotherapeutics available at scale. More information is available at www.mindmazetherapeutics.com.
